Infinity Pharmaceuticals Inc. had high expectations for the Phase II DYNAMO clinical trial testing its PI3K inhibitor duvelisib in indolent non-Hodgkin lymphoma (iNHL), but the company didn't sugarcoat the results: while the trial's primary endpoint was met, the data were not as good as hoped.
The results were so disappointing that Infinity and AbbVie Inc. are discussing potential changes to their partnership and Infinity is rethinking its business strategy, which was dependent on regulatory...